Perfil de la empresa · Healthcare

AstraZeneca PLC

AZN · EE. UU.
Bolsa
EE. UU.
País / Región
USA
Fecha de salida a bolsa
17 de mayo de 1993
Empleados
96.100
Precio actual
$174.93
En vivo · 18 de junio de 2026
Compra razonable
≤ $132
Entrada con margen de seguridad
Puntuación de crecimiento Baillie
51/100
Media
Valor intrínseco · Rango en tres niveles Precio actual $174.93 En vivo · Dentro del rango de valor intrínseco razonable

Rango de valoración compuesto · conservador $124–$132 / razonable $166–$224 / optimista $242–$264. A $174.93, Dentro del rango de valor intrínseco razonable.

Al publicar $178.75 (15 de junio de 2026)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; and a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Capitalización278,7 mil MUS$
Ingresos (TTM)60,44 mil MUS$
EBITDA20,03 mil MUS$
Margen neto17,19 %
ROE23,48 %
PER (TTM)27,11
PER previsto17,67
PEG1,39
BPA6,63 US$
Rentabilidad por dividendo1,72 %
Rango de 52 semanas134,85 US$ – 210,50 US$
Precio objetivo de analistas224,49 US$
Recomendación de analistas4.6 / 5

Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.

Historia

PróximamenteEsta sección se está completando; vuelve pronto.

Posición en el sector

PróximamenteEsta sección se está completando; vuelve pronto.